845OPhase III randomized, sequential, open-label study to...

Annals of Oncology 2017 / 09 Vol. 28; Iss. suppl_5

845OPhase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)

Retz, M., Bedke, J., Herrmann, E., Grimm, M-O., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Frank, M., Gschwend, J.E.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx371
Date:
September, 2017
File:
PDF, 75 KB
english, 2017
Conversion to is in progress
Conversion to is failed